SCHEMBL167501

SCHEMBL167501

[2H]C([2H])(c1ccnc(N)c1)n1ccc2c(NC(=O)Nc3ccccc3C)cccc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDX3X O00571 2/20 0.41
RAB9A P51151 3/20 0.40
NPC1 O15118 2/20 0.40
MEN1 O00255 4/20 0.39
KMT2A Q03164 4/20 0.39
MAPT P10636 4/20 0.39
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
HCK P08631 1/20 0.38
MAPK12 P53778 1/20 0.38
MAPK14 Q16539 1/20 0.38
ROCK1 Q13464 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
STAT3 P40763 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15077847 0.90 TRPV1 (0.46) MEN1KMT2AMAPTHTTTP53
SCHEMBL168670 0.90 MAPT (0.40) MEN1KMT2AMAPTKDM4EROCK1
SCHEMBL165124 0.89 RAB9A (0.43) RAB9AMEN1KMT2AMAPTKDM4E
SCHEMBL167600 0.89 EPHB4 (0.39) RAB9ANPC1MEN1KMT2AMAPT
SCHEMBL164013 0.89 RAB9A (0.40) RAB9ANPC1MEN1KMT2AMAPT
SCHEMBL166419 0.89 NR1I2 (0.41) RAB9ANPC1MEN1KMT2AMAPT
SCHEMBL169174 0.88 KDR (0.43) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL167481 0.88 MAPT (0.43) MEN1KMT2AMAPTKDM4EALDH1A1
SCHEMBL167748 0.87 ROCK1 (0.39) MEN1KMT2AMAPTKDM4EALDH1A1
SCHEMBL168470 0.87 KDR (0.45) RAB9ANPC1MAPTROCK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130165475-A1 DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS ASCEPION PHARMACEUTICALS, INC. (CN) 2013-06-27 US claimed
EP-2611806-A1 DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS Ascepion Pharmaceuticals, Inc. (CN) 2013-07-10 EP disclosed
US-20130165475-A1 DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS ASCEPION PHARMACEUTICALS, INC. (CN) 2013-06-27 US disclosed
WO-2012028106-A1 DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS ASCEPION PHARMACEUTICALS, INC. (CN) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165475-A1 DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS CDK2, CDK1, CDK3 DDX3X 1037/4885RAB9A 2322/4885NPC1 3123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.